

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)



(10) International Publication Number
WO 2021/159118 A8

(51) International Patent Classification:

A61K 48/00 (2006.01) A61K 39/12 (2006.01)
A61K 9/127 (2006.01) A61K 39/00 (2006.01)
A61K 9/00 (2006.01) A61K 38/00 (2006.01)
A61K 9/14 (2006.01) C07H 21/04 (2006.01)

(21) International Application Number:

PCT/US2021/017149

(22) International Filing Date:

08 February 2021 (08.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/971,834 07 February 2020 (07.02.2020) US
63/058,463 29 July 2020 (29.07.2020) US
63/130,581 24 December 2020 (24.12.2020) US

(71) Applicant: **RNAIMMUNE, INC.** [US/US]; 401 Professional Drive, Suite 280, Gaithersburg, MD 20879 (US).

(72) Inventors: **TANG, Shenggao**; c/o RNAImmune, Inc., 401 Professional Drive, Suite 280, Gaithersburg, MD 20879 (US). **SHEN, Dong**; c/o RNAImmune, Inc., 401 Professional Drive, Suite 280, Gaithersburg, MD 20879 (US). **LU, Chun**; c/o RNAImmune, Inc., 401 Professional Drive, Suite 280, Gaithersburg, MD 20879 (US). **HE, Ziyang**; c/o RNAImmune, Inc., 401 Professional Drive, Suite 280, Gaithersburg, MD 20879 (US). **HE, Jiayi**; c/o RNAImmune, Inc., 401 Professional Drive, Suite 280, Gaithersburg, MD 20879 (US). **LU, Patrick, Y.**; c/o RNAImmune, Inc., 401 Professional Drive, Suite 280, Gaithersburg, MD 20879 (US).

(74) Agent: **KONSKI, Antoinette, F.** et al.; Foley & Lardner LLP, 3000 K Street, NW, Suite 600, Washington, DC 20007-5109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) Date of publication of the international search report:

28 October 2021 (28.10.2021)

(48) Date of publication of this corrected version:

22 September 2022 (22.09.2022)

(15) Information about Correction:

see Notice of 22 September 2022 (22.09.2022)

(54) Title: COMPOSITION AND METHOD OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION

(57) Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.



WO 2021/159118 A8